Apatinib for non-first-line treatment as an anti-angiogenesis agent in metastatic cancer:an open-label,single-arm phase II trial

Status

Recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OIC-17013238

Enrollment

Unknown

Registered

2017-11-04

Start date

2015-08-20

Completion date

Unknown

Last updated

2017-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic cancer

Interventions

Experience group:Take Apatinib

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 85 years old male or female; 2. The advanced tumor with diagnose by histopathology and / or cytology advanced tumor, and with measurable gross tumor; 3. The patients with first-line treatment failure; 4. ECOG PS 0-2 score; 5. The patients with main organs of normal function; 6. The expected survival time more than 3 months; 7. the doctor plans to use apatinib in the treatment of patients; 8. The patients who voluntary and signed informed consent.;Inclusion criteria: 1. Aged 18 to 85 years old male or female; 2. The advanced tumor with diagnose by histopathology and / or cytology advanced tumor, and with measurable gross tumor; 3. The patients with first-line treatment failure; 4. ECOG PS 0-2 score; 5. The patients with main organs of normal function; 6. The expected survival time more than 3 months; 7. the doctor plans to use apatinib in the treatment of patients; 8. The patients who voluntary and signed informed consent.;Inclusion criteria: 1. Aged 18 to 85 years old male or female; 2. The advanced tumor with diagnose by histopathology and / or cytology advanced tumor, and with measurable gross tumor; 3. The patients with first-line treatment failure; 4. ECOG PS 0-2 score; 5. The patients with main organs of normal function; 6. The expected survival time more than 3 months; 7. the doctor plans to use apatinib in the treatment of patients; 8. The patients who voluntary and signed informed consent.;Inclusion criteria: 1. Aged 18 to 85 years old male or female; 2. The advanced tumor with diagnose by histopathology and / or cytology advanced tumor, and with measurable gross tumor; 3. The patients with first-line treatment failure; 4. ECOG PS 0-2 score; 5. The patients with main organs of normal function; 6. The expected survival time more than 3 months; 7. the doctor plans to use apatinib in the treatment of patients; 8. The patients who voluntary and signed informed consent.;Inclusion criteria: 1. Aged 18 to 85 years old male or female; 2. The advanced tumor with diagnose by histopathology and / or cytology advanced tumor, and with measurable gross tumor; 3. The patients with first-line treatment failure; 4. ECOG PS 0-2 score; 5. The patients with main organs of normal function; 6. The expected survival time more than 3 months; 7. the doctor plans to use apatinib in the treatment of patients; 8. The patients who voluntary and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. The patients with hypertension, the antihypertensive drug treatment can not be reduced to the normal range; 2. The patients with a variety of factors of oral drug absorption; 3. With the risk of gastrointestinal bleeding of patients can not into the group; 4. The patients with symptoms of central nervous system metastasis; 5. The pregnant or lactating women; 6. Other patients that the doctors don't think for suitable.;Exclusion criteria: 1. The patients with hypertension, the antihypertensive drug treatment can not be reduced to the normal range; 2. The patients with a variety of factors of oral drug absorption; 3. With the risk of gastrointestinal bleeding of patients can not into the group; 4. The patients with symptoms of central nervous system metastasis; 5. The pregnant or lactating women; 6. Other patients that the doctors don't think for suitable.;Exclusion criteria: 1. The patients with hypertension, the antihypertensive drug treatment can not be reduced to the normal range; 2. The patients with a variety of factors of oral drug absorption; 3. With the risk of gastrointestinal bleeding of patients can not into the group; 4. The patients with symptoms of central nervous system metastasis; 5. The pregnant or lactating women; 6. Other patients that the doctors don't think for suitable.;Exclusion criteria: 1. The patients with hypertension, the antihypertensive drug treatment can not be reduced to the normal range; 2. The patients with a variety of factors of oral drug absorption; 3. With the risk of gastrointestinal bleeding of patients can not into the group; 4. The patients with symptoms of central nervous system metastasis; 5. The pregnant or lactating women; 6. Other patients that the doctors don't think for suitable.;Exclusion criteria: 1. The patients with hypertension, the antihypertensive drug treatment can not be reduced to the normal range; 2. The patients with a variety of factors of oral drug absorption; 3. With the risk of gastrointestinal bleeding of patients can not into the group; 4. The patients with symptoms of central nervous system metastasis; 5. The pregnant or lactating women; 6. Other patients that the doctors don't think for suitable.

Design outcomes

Primary

Measure	Time frame
Progression Free Survival;	—

Countries

China

Contacts

Public ContactYiyu Lu;Yiyu Lu;Yiyu Lu;Yiyu Lu;Yiyu Lu ;;;;

The People's Hospital of Nanhai Foshan;The People's Hospital of Nanhai Foshan;The People's Hospital of Nanhai Foshan;The People's Hospital of Nanhai Foshan;The People's Hospital of Nanhai Foshan

lu_yiyu@163.com;lu_yiyu@163.com;lu_yiyu@163.com;lu_yiyu@163.com;lu_yiyu@163.com+86 13925996488;+86 13925996488;+86 13925996488;+86 13925996488;+86 13925996488

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026